Cellevate Set To Launch Innovative Nanofiber Microcarriers For Enhanced Viral Vector Production At CPHI Milan Event

Cellevate, a cutting-edge biotech firm focused on advancing cell culture systems, is set to pre-launch the world's first nanofiber microcarrier designed specifically for gene therapy at CPHI Milan, taking place from October 8-10, 2024. Cellevat3d® nanofiber microcarriers offer an impressive 60 times more surface area for cell growth compared to traditional systems, significantly boosting yield and productivity in the upstream bioprocessing of gene therapy. 

Designed for stirred tank bioreactors, these microcarriers are versatile and can be used in various applications, including gene therapy, pluripotent stem cell (PSC) expansion, organoid formation, HEK-based recombinant protein production, and HEK-based vaccine development.

Attendees at CPHI Milan can pre-order Cellevat3d® nanofiber microcarriers between October 8-10, 2024. To discover more, schedule a meeting with Laura Chirica, CEO of Cellevate, and Bettina Berendsen, Strategic Advisor and Board Observer at Cellevate. The official product launch will occur at BIO-Europe in Stockholm, Sweden, from November 4-6, 2024.

Laura Chirica, PhD CEO, of Cellevate, said in a statement, “Scalable, sustainable and single use, Cellevat3d® nanofiber microcarriers closely mimic the human extracellular environment, providing higher cell densities and enhancing yield for viral vector production compared to current standard microcarriers based processes. Our nanofiber microcarriers effectively address the key challenges of low productivity and high manufacturing costs facing the industry.”

She further continued, “With this pre-launch of Cellevat3d® nanofiber microcarriers starter pack, at CPHI Milan, we’re excited to provide early access to a completely new category of cell culture systems currently unavailable on the market. Cellevat3d® nanofiber-based cell culture systems truly have the potential to transform biomanufacturing for advanced therapies and take a significant step toward making these therapies more accessible to patients.”